PMID- 25543697
OWN - NLM
STAT- MEDLINE
DCOM- 20151007
LR  - 20181202
IS  - 0253-2727 (Print)
IS  - 0253-2727 (Linking)
VI  - 35
IP  - 12
DP  - 2014 Dec
TI  - [Characteristics and treatment outcomes in 822 adult patients with acute myeloid 
      leukemia:a single center experience].
PG  - 1058-64
LID - 10.3760/cma.j.issn.0253-2727.2014.12.003 [doi]
AB  - OBJECTIVE: To investigate the characteristics and the short- or long-term 
      treatment outcomes of the adult patients with acute myeloid leukemia (AML) in 
      China. METHODS: From 1999 to 2010, 822 adult cases with AML were enrolled, 
      diagnosed and classified by the FAB and WHO criteria, respectively. The treatment 
      outcomes and prognostic factors were analyzed retrospectively. RESULTS: In all 
      patients with a median age of 38.5(15-83) years, acute monoblastic and monocytic 
      leukemia (M5), AML with t(15;17)/PML-RARalpha (APL) and AML with 
      t(8;21)/AML1-ETO(M2b) were the most common subtypes, accounting for 29.7%, 20.9% 
      and 14.6% respectively. In APL patients, CR was achieved in 95.2%, with an early 
      death (ED) rate of 4.8%. And the estimated overall survival (OS) and disease-free 
      survival (DFS) at 5 year was 87.5% and 88.8%, respectively. Patients with other 
      AML subtype (Non-APL) revealed a CR rate of 82.0%, ED of 4.3%, and estimated 
      5-year OS and DFS both of 48.8%. The OS rate of Non-APL patients at 3-year varied 
      significantly (P<0.01) among three prognostic groups by cytogenetic risk 
      stratification:favorable, 69.5%; intermediate, 52.8%; unfavorable, 29.8%. The 
      prognostic factors for OS among Non-APL included age, cytogenetic abnormalities, 
      courses of the median/high-dose cytarabine and allogeneic hematopoietic stem cell 
      transplantation. CONCLUSION: When compared with the previous reports, the AML 
      patients in our study were younger and showed a different subtype distribution. 
      Treatment outcomes of APL and Non-APL were just the same as those in 
      international leukemia centers. Chemotherapy by risk stratification, after 
      diagnosis and classification according to the WHO criteria, is a key point to 
      improve the outcomes in AML.
FAU - Lin, Dong
AU  - Lin D
AD  - Leukemia Centre, Institute of Hematology and Blood Diseases Hospital, CAMS & 
      PUMC, Tianjin 300020, China.
FAU - Zhou, Chunlin
AU  - Zhou C
AD  - Leukemia Centre, Institute of Hematology and Blood Diseases Hospital, CAMS & 
      PUMC, Tianjin 300020, China.
FAU - Wei, Hui
AU  - Wei H
AD  - Leukemia Centre, Institute of Hematology and Blood Diseases Hospital, CAMS & 
      PUMC, Tianjin 300020, China.
FAU - Liu, Bingcheng
AU  - Liu B
AD  - Leukemia Centre, Institute of Hematology and Blood Diseases Hospital, CAMS & 
      PUMC, Tianjin 300020, China.
FAU - Wang, Ying
AU  - Wang Y
AD  - Leukemia Centre, Institute of Hematology and Blood Diseases Hospital, CAMS & 
      PUMC, Tianjin 300020, China.
FAU - Liu, Kaiqi
AU  - Liu K
AD  - Leukemia Centre, Institute of Hematology and Blood Diseases Hospital, CAMS & 
      PUMC, Tianjin 300020, China.
FAU - Li, Wei
AU  - Li W
AD  - Leukemia Centre, Institute of Hematology and Blood Diseases Hospital, CAMS & 
      PUMC, Tianjin 300020, China.
FAU - Gong, Benfa
AU  - Gong B
AD  - Leukemia Centre, Institute of Hematology and Blood Diseases Hospital, CAMS & 
      PUMC, Tianjin 300020, China.
FAU - Wang, Jinyu
AU  - Wang J
AD  - Leukemia Centre, Institute of Hematology and Blood Diseases Hospital, CAMS & 
      PUMC, Tianjin 300020, China.
FAU - Wei, Shuning
AU  - Wei S
AD  - Leukemia Centre, Institute of Hematology and Blood Diseases Hospital, CAMS & 
      PUMC, Tianjin 300020, China.
FAU - Zhang, Guangji
AU  - Zhang G
AD  - Leukemia Centre, Institute of Hematology and Blood Diseases Hospital, CAMS & 
      PUMC, Tianjin 300020, China.
FAU - Zhao, Xingli
AU  - Zhao X
AD  - Leukemia Centre, Institute of Hematology and Blood Diseases Hospital, CAMS & 
      PUMC, Tianjin 300020, China.
FAU - Li, Yan
AU  - Li Y
AD  - Leukemia Centre, Institute of Hematology and Blood Diseases Hospital, CAMS & 
      PUMC, Tianjin 300020, China.
FAU - Liu, Yuntao
AU  - Liu Y
AD  - Leukemia Centre, Institute of Hematology and Blood Diseases Hospital, CAMS & 
      PUMC, Tianjin 300020, China.
FAU - Gong, Xiaoyuan
AU  - Gong X
AD  - Leukemia Centre, Institute of Hematology and Blood Diseases Hospital, CAMS & 
      PUMC, Tianjin 300020, China.
FAU - Sun, Mingyuan
AU  - Sun M
AD  - Leukemia Centre, Institute of Hematology and Blood Diseases Hospital, CAMS & 
      PUMC, Tianjin 300020, China.
FAU - Lu, Yuan
AU  - Lu Y
AD  - Leukemia Centre, Institute of Hematology and Blood Diseases Hospital, CAMS & 
      PUMC, Tianjin 300020, China.
FAU - Mi, Yingchang
AU  - Mi Y
AD  - Leukemia Centre, Institute of Hematology and Blood Diseases Hospital, CAMS & 
      PUMC, Tianjin 300020, China.
FAU - Wang, Jianxiang
AU  - Wang J
AD  - Leukemia Centre, Institute of Hematology and Blood Diseases Hospital, CAMS & 
      PUMC, Tianjin 300020, China.
LA  - chi
PT  - Journal Article
PL  - China
TA  - Zhonghua Xue Ye Xue Za Zhi
JT  - Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
JID - 8212398
RN  - 0 (Oncogene Proteins, Fusion)
RN  - 0 (promyelocytic leukemia-retinoic acid receptor alpha fusion oncoprotein)
RN  - 04079A1RDZ (Cytarabine)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - China
MH  - Cytarabine
MH  - Disease-Free Survival
MH  - Hematopoietic Stem Cell Transplantation
MH  - Humans
MH  - *Leukemia, Myeloid, Acute
MH  - Middle Aged
MH  - Oncogene Proteins, Fusion
MH  - Retrospective Studies
MH  - Survival Rate
MH  - Treatment Outcome
MH  - Young Adult
EDAT- 2014/12/30 06:00
MHDA- 2015/10/08 06:00
CRDT- 2014/12/30 06:00
PHST- 2014/12/30 06:00 [entrez]
PHST- 2014/12/30 06:00 [pubmed]
PHST- 2015/10/08 06:00 [medline]
AID - 10.3760/cma.j.issn.0253-2727.2014.12.003 [doi]
PST - ppublish
SO  - Zhonghua Xue Ye Xue Za Zhi. 2014 Dec;35(12):1058-64. doi: 
      10.3760/cma.j.issn.0253-2727.2014.12.003.